A clinical research consortium sponsored by NIAID and JDRF
This core provides state-of-the-art testing for HLA antibodies. Serum samples collected from patients are evaluated for the presence or absence of donor-specific HLA alloantibody, a risk factor for transplant recipients if present at the time of transplantation or if produced de novo following transplantation.
Testing is performed using HLA-specific microparticles (FlowPRATM) and analyzed by flow cytometry. For samples that test positive, HLA antibody specificity is assessed using additional antigen coated micro-particles and flow cytometry (flow-specific beads and single-antigen beads).
The core also provides donor-specific crossmatch testing with cryopreserved cells or testing against a panel of cryopreserved lymphocytes. Flow cytometric crossmatching is conducted using a standardized 3-color method utilizing donor mononuclear cells.
The laboratory may also perform STAT testing for specific patients. In instances where patients may be experiencing a rejection episode, knowledge of the patient's donor-specific HLA antibody profile can aid in treatment.
